DrugPatentWatch Database Preview
Metuchen Pharms Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for METUCHEN PHARMS, and what generic alternatives to METUCHEN PHARMS drugs are available?
METUCHEN PHARMS has one approved drug.
There are two US patents protecting METUCHEN PHARMS drugs.
There are fifty-three patent family members on METUCHEN PHARMS drugs in twenty-six countries and eleven supplementary protection certificates in eleven countries.
Summary for Metuchen Pharms
| International Patents: | 53 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Metuchen Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-003 | Apr 27, 2012 | RX | Yes | Yes | 6,656,935 | Start Trial | Y | Y | Start Trial | ||
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-002 | Apr 27, 2012 | RX | Yes | No | 7,501,409 | Start Trial | Y | Start Trial | |||
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-001 | Apr 27, 2012 | RX | Yes | No | 7,501,409 | Start Trial | Y | Start Trial | |||
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-002 | Apr 27, 2012 | RX | Yes | No | 6,656,935 | Start Trial | Y | Y | Start Trial | ||
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-001 | Apr 27, 2012 | RX | Yes | No | 6,656,935 | Start Trial | Y | Y | Start Trial | ||
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-003 | Apr 27, 2012 | RX | Yes | Yes | 7,501,409 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for METUCHEN PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 50 mg, 100 mg and 200 mg | ➤ Subscribe | 2016-04-27 |
International Patents for Metuchen Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 1316316 | Start Trial |
| Australia | 7311800 | Start Trial |
| Japan | 4588973 | Start Trial |
| Australia | 4114201 | Start Trial |
| Norway | 322038 | Start Trial |
| Denmark | 1219609 | Start Trial |
| Mexico | PA03001958 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Metuchen Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1219609 | 1390047-7 | Sweden | Start Trial | PRODUCT NAME: AVANAFIL; REG. NO/DATE: EU/1/13/841 20130621 |
| 1219609 | 2013C/051 | Belgium | Start Trial | PRODUCT NAME: AVANAFIL; AUTHORISATION NUMBER AND DATE: EU/1/13/841 20130624 |
| 1219609 | 13C0050 | France | Start Trial | PRODUCT NAME: AVANAFIL; REGISTRATION NO/DATE: EU/1/13/841 20130621 |
| 1219609 | 476 | Finland | Start Trial | |
| 1219609 | CA 2013 00040 | Denmark | Start Trial | |
| 1219609 | C300618 | Netherlands | Start Trial | PRODUCT NAME: AVANAFIL; REGISTRATION NO/DATE: EU/1/13/841 20130621 |
| 1219609 | C01219609/01 | Switzerland | Start Trial | PRODUCT NAME: AVANAFIL; REGISTRATION NO/DATE: SWISSMEDIC 65275 22.01.2016 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
